Translation
Notice: This document is an excerpt translation of the original Japanese document and is only for reference purposes. In the event of any discrepancy between this translated document and the original Japanese document, the latter shall prevail.
Summary of Non-Consolidated Financial Results
for the Three Months Ended June 30, 2020
(Based on Japanese GAAP)
July 31, 2020 | ||||
Company name: | DAIKEN MEDICAL CO., LTD. | |||
Stock exchange listing: | Tokyo | |||
Stock code: | 7775 | URL http://www.daiken-iki.co.jp | ||
Representative: | President | Keiichi Yamada | ||
Inquiries: | General Manager, Business Control Division | Kenji Tamamaki | TEL 06-6231-9917 | |
Scheduled date to file Quarterly Securities Report: | August 3, 2020 | |||
Scheduled date to commence dividend payments: | - | |||
Preparation of supplementary material on quarterly financial results: | No | |||
Holding of quarterly financial results meeting: | No |
(Amounts less than one million yen are rounded down)
1. Non-consolidated financial results for the three months ended June 30, 2020 (from April 1, 2020 to June 30, 2020)
(1) Non-consolidated operating results (cumulative) | Percentages indicate year-on-year changes | |||||||||||||||
Net sales | Operating profit | Ordinary profit | Profit | |||||||||||||
Millions of yen | % | Millions of yen | % | Millions of yen | % | Millions of yen | % | |||||||||
Three months ended June 30, 2020 | 1,790 | (13.0) | 191 | (38.4) | 191 | (41.2) | 136 | (41.4) | ||||||||
Three months ended June 30, 2019 | 2,057 | (1.6) | 310 | (11.4) | 325 | (7.2) | 232 | (8.9) | ||||||||
Earnings per share | Diluted earnings per share | |||||||||||||||
Yen | Yen | |||||||||||||||
Three months ended June 30, 2020 | 4.75 | - | ||||||||||||||
Three months ended June 30, 2019 | 8.11 | - | ||||||||||||||
(2) Non-consolidated financial position | ||||||||||||||||
Total assets | Net assets | Equity ratio | ||||||||||||||
Millions of yen | Millions of yen | % | ||||||||||||||
As of June 30, 2020 | 10,890 | 5,902 | 54.2 | |||||||||||||
As of March 31, 2020 | 10,997 | 6,081 | 55.3 | |||||||||||||
2. Cash dividends | ||||||||||||||||
Annual dividends per share | ||||||||||||||||
1st quarter-end | 2nd quarter-end | 3rd quarter-end | Fiscal year-end | Total | ||||||||||||
Yen | Yen | Yen | Yen | Yen | ||||||||||||
Year ended March 31, 2020 | - | 9.00 | - | 11.00 | 20.00 | |||||||||||
Year ending March 31, 2021 | - | |||||||||||||||
Year ending March 31, 2021 (Forecast) | 9.00 | - | 11.00 | 20.00 |
3. Forecast of non-consolidated financial results for the year ending March 31, 2021 (from April 1, 2020 to March 31, 2021)
Percentages indicate year-on-year changes
Net sales | Operating profit | Ordinary profit | Profit | Earnings per share | ||||||
Six months ending | Millions of yen | % | Millions of yen | % | Millions of yen | % | Millions of yen | % | Yen | |
3,970 | (6.6) | 520 | (8.0) | 560 | (3.4) | 400 | (3.4) | 13.92 | ||
September 30, 2020 | ||||||||||
Full year | 8,400 | (1.4) | 1,160 | (2.9) | 1,200 | (0.8) | 860 | 0.1 | 29.94 |
1
4. Notes
- Application of special accounting methods for preparing quarterly non-consolidated financial statements: Yes
- Changes in accounting policies, changes in accounting estimates, and restatement of prior period financial statements
Changes in accounting policies due to revisions to accounting standards and other regulations: | No |
Changes in accounting policies due to other reasons: | No |
Changes in accounting estimates: | No |
Restatement of prior period financial statements: | No |
(3) Number of issued shares (common shares)
Total number of issued shares at the end of the period (including treasury shares)
As of June 30, 2020 | 31,840,000 | shares | As of March 31, 2020 | 31,840,000 | shares | |
Number of treasury shares at the end of the period | ||||||
As of June 30, 2020 | 3,111,559 | shares | As of March 31, 2020 | 3,111,559 | shares | |
Average number of shares during the period (cumulative from the beginning of the fiscal year) | ||||||
Three months ended June 30, 2020 | 28,728,441 | shares | Three months ended June 30, 2019 | 28,728,441 | shares |
2
Quarterly non-consolidated financial statements
Non-consolidated balance sheets
(Thousands of yen) | |||
As of March 31, 2020 | As of June 30, 2020 | ||
Assets | |||
Current assets | |||
Cash and deposits | 2,365,400 | 2,318,167 | |
Notes and accounts receivable - trade | 1,904,574 | 1,571,149 | |
Electronically recorded monetary claims - operating | 821,808 | 818,660 | |
Finished goods | 770,451 | 1,011,402 | |
Work in process | 67,009 | 61,340 | |
Raw materials | 335,991 | 371,874 | |
Other | 139,276 | 136,610 | |
Allowance for doubtful accounts | (92) | (92) | |
Total current assets | 6,404,420 | 6,289,111 | |
Non-current assets | |||
Property, plant and equipment | |||
Buildings, net | 2,104,782 | 2,082,189 | |
Land | 1,703,670 | 1,703,670 | |
Other, net | 492,475 | 523,102 | |
Total property, plant and equipment | 4,300,929 | 4,308,963 | |
Intangible assets | 29,313 | 29,372 | |
Investments and other assets | |||
Deferred tax assets | 194,818 | 194,818 | |
Other | 92,916 | 92,423 | |
Allowance for doubtful accounts | (24,650) | (24,650) | |
Total investments and other assets | 263,083 | 262,590 | |
Total non-current assets | 4,593,325 | 4,600,926 | |
Total assets | 10,997,746 | 10,890,037 |
3
(Thousands of yen) | |||
As of March 31, 2020 | As of June 30, 2020 | ||
Liabilities | |||
Current liabilities | |||
Notes and accounts payable - trade | 1,061,873 | 1,107,145 | |
Short-term borrowings | 800,000 | 1,200,000 | |
Current portion of long-term borrowings | 898,032 | 877,796 | |
Income taxes payable | 180,854 | 66,160 | |
Accrued expenses | 445,687 | 486,994 | |
Other | 396,226 | 278,893 | |
Total current liabilities | 3,782,673 | 4,016,990 | |
Non-current liabilities | |||
Long-term borrowings | 1,091,892 | 922,443 | |
Other | 41,568 | 48,443 | |
Total non-current liabilities | 1,133,460 | 970,886 | |
Total liabilities | 4,916,133 | 4,987,877 | |
Net assets | |||
Shareholders' equity | |||
Share capital | 495,875 | 495,875 | |
Capital surplus | 400,875 | 400,875 | |
Retained earnings | 7,011,444 | 6,831,992 | |
Treasury shares | (1,826,582) | (1,826,582) | |
Total shareholders' equity | 6,081,612 | 5,902,160 | |
Total net assets | 6,081,612 | 5,902,160 | |
Total liabilities and net assets | 10,997,746 | 10,890,037 |
4
Non-consolidated statements of income (cumulative)
(Thousands of yen) | |||
Three months ended | Three months ended | ||
June 30, 2019 | June 30, 2020 | ||
Net sales | 2,057,730 | 1,790,803 | |
Cost of sales | 1,090,920 | 981,733 | |
Gross profit | 966,809 | 809,070 | |
Selling, general and administrative expenses | 656,748 | 617,979 | |
Operating profit | 310,061 | 191,090 | |
Non-operating income | |||
Gain on forfeiture of unclaimed dividends | 435 | 814 | |
Compensation income | 568 | - | |
Subsidy income | 15,581 | - | |
Other | 372 | 532 | |
Total non-operating income | 16,957 | 1,347 | |
Non-operating expenses | |||
Interest expenses | 1,210 | 955 | |
Other | 171 | 106 | |
Total non-operating expenses | 1,381 | 1,061 | |
Ordinary profit | 325,637 | 191,376 | |
Extraordinary losses | |||
Loss on retirement of non-current assets | 0 | 145 | |
Total extraordinary losses | 0 | 145 | |
Profit before income taxes | 325,637 | 191,230 | |
Income taxes | 92,644 | 54,670 | |
Profit | 232,993 | 136,560 |
5
Attachments
- Original document
- Permalink
Disclaimer
DAIKEN Medical Co. Ltd. published this content on 05 August 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 05 August 2020 07:06:11 UTC